Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (69,652)	$ (70,253)	$ (38,136)	$ (39,805)	$ (139,905)	$ (77,941)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense					13,132	4,990
Provisions for credit losses					(308)	(57)	$ 714
Amortization of deferred contract acquisition costs					847	731
Amortization of deferred contract fulfillment costs					288	351
Noncash compensation costs incurred by selling shareholders					3,993
Stock-based compensation expense					27,598	19,368
Loss on equity method investment	551		722		762	1,541
Deferred income taxes					(1,164)
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable					5,763	9,809
Inventories					(391)	199
Deferred contract acquisition costs					(1,135)	(618)
Prepaid expenses and other current assets					(1,714)	284
Other assets					489	184
Accounts payable					(6,525)	(624)
Accrued expenses and other current liabilities					(490)	(16,063)
Other long-term liabilities					(15)	(38)
Deferred revenue					(6,624)	(9,506)
Net cash used in operating activities					(105,399)	(67,390)
Cash flows from investing activities:
Purchases of property and equipment					(58)	(283)
Investment in less than majority owned joint venture					(1,960)	(2,548)
Purchases of investments					(499,223)
Proceeds from sales and maturities of investments					124,981	100,000
Net cash used in and provided by investing activities					(376,260)	97,169
Cash flows from financing activities:
Proceeds from exercise of common stock options					4,465	16,733
Proceeds from employee stock purchase plan					1,501
Payments for the purchase of treasury stock						(11,628)
Payment of deferred offering costs						(1,613)
Proceeds from Section 16(b) disgorgement					295
Payment of contingent consideration					(11,790)
Net cash used in and provided by financing activities					(5,529)	3,492
Effect of exchange rates changes on cash, cash equivalents, and restricted cash					(2,039)
Net decrease in cash, cash equivalents, and restricted cash					(489,227)	33,271
Cash, cash equivalents, and restricted cash at beginning of period		$ 747,211		$ 942,711	747,211	942,711	942,711
Cash, cash equivalents, and restricted cash at end of period	257,984		975,982		257,984	975,982	747,211
Cash, cash equivalents, and restricted cash at end of period:
Cash and cash equivalents	257,189		975,187		257,189	975,187	746,416
Restricted cash	795		795		795	795
Total cash, cash equivalents, and restricted cash at end of period	$ 257,984		$ 975,982		257,984	975,982	$ 747,211
Supplemental disclosure of cash flow information:
Cash (refunded) paid for income taxes					13	955
Supplemental disclosure of non-cash investing and financing activities:
Issuance of common stock in settlement of earnout					$ 17,243
Receivable related to exercise of common stock options						$ 71